Skip to main content

Advertisement

Table 3 Univariate and Multivariate Analysis by a Cox Proportional Hazards Regression Model in Cohort

From: Prognostic value of biomarkers EpCAM and αB-crystallin associated with lymphatic metastasis in breast cancer by iTRAQ analysis

Variable OS
Univariate Multivariate
HR (95% CI) P Value HR (95% CI) P Value
Age, years (>  45 vs. ≤ 45) 0.898 (0.581–1.390) 0.630 NA  
ER (positive vs. negative) 1.114 (0.711–1.745) 0.637 NA  
PR (positive vs. negative) 1.213 (0.775–1.899) 0.398 NA  
CrebB-2 (positive vs. negative) 1.128 (0.705–1.806) 0.615 NA  
Menstrual history (presence vs. absence) 1.381 (0.851–2.241) 0.191 NA  
Operation   0.649 NA  
 Modified radical mastectomy vs. radical correction 1.150 (0.727–1.820) 0.550 NA  
 Other operation vs. radical correction 0.642 (0.155–2.663) 0.542 NA  
FADD (positive vs. negative) 1.580 (0.995–2.509) 0.053 NA  
NDRG1 (low vs. high) 1.302 (0.762–2.226) 0.335 NA  
CRYAB (positive vs. negative) 1.561 (0.902–2.701) 0.112 NA  
Tumor diameter, cm   0.072   NS
  > 5 vs. > 2 and ≤ 5 1.923 (1.019–3.636) 0.043   
  > 5 vs. ≤2 2.230 (1.093–4.549) 0.027   
TNM stage   < 0.0001   NS
 III vs. I 4.329 (1.824–10.273) 0.001   
 III vs. II 2.101 (1.333–3.311) 0.001   
Histology stage (poorly differentiation vs. high-middle differentiation) 2.286 (1.100–4.751) 0.027   NS
Histology type (lobular carcinoma vs. duct carcinoma) 1.720 (1.025–2.886) 0.040 1.846 (1.093–3.118) 0.022
Lymph node metastasis (presence vs. absence) 2.810 (1.694–4.662) < 0.0001 2.801 (1.688–4.649) < 0.0001
EpCAM (positive vs. negative) 2.306 (1.218–4.367) 0.010 2.585 (1.351–4.944) 0.004
  1. Data in bold are P values < 0.05